Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVOLVE: OMNI Surgical System vs Medical Treatment in POAG
NCT06407973Phase 4Terminated
- Sponsor
- Sight Sciences
- Start
- Aug 2024
- Primary completion
- Jan 2025
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial (2 arms), sponsored by Sight Sciences. Primary endpoint: Subjects with a >= 20% reduction in IOP at 12 months. Started Aug 2024; status: terminated.
Beyond the preview
Go deeper on NCT06407973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06407973.